Literature DB >> 15196797

Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.

M A Delfino1, A V Stefano, J E Ferrario, I R E Taravini, M G Murer, O S Gershanik.   

Abstract

Repeated treatment with dopamine (DA) receptor agonists strongly potentiates contralateral turning behavior due to selective stimulation of D1 or D2-class receptors in 6-hydroxydopamine (6-OHDA)-lesioned rats. This phenomenon, referred to as sensitization, is believed to be related to the motor response complications (dyskinesias, on-off states) that occur during chronic administration of levodopa in Parkinson's disease patients. In recent years a new method for the evaluation of abnormal involuntary movements (AIMs) secondary to dopaminergic stimulation in 6-OHDA-lesioned rats was described. These AIMs resemble dyskinesias as seen in parkinsonian patients under levodopa therapy. Our objective was to evaluate the effects of repeated treatment with different regimes of DA agonists on turning behavior and on an AIMs scale in 6-OHDA lesioned rats, with the aim of discriminating between drugs with different dyskinesia-inducing potential. In addition, we explored the effects of a previous exposure to a DA agonist (priming) on the behavioral response to the subsequent administration of a DA agonist with the same or different pharmacologic profile. Our results show that in apomorphine-treated rats, rotational behavior and AIMs run a parallel course of enhancement, while in those receiving quinpirole there is a dissociation, suggesting that they could be mediated by different mechanisms. The finding of a significant priming effect on subsequent testing of 6-OHDA lesioned rats should be borne in mind as the use of these pharmacological tests in the screening of well lesioned animals could lead to an erroneous interpretation of further results on dyskinesias and rotational behavior. Copyright 2003 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196797     DOI: 10.1016/j.bbr.2003.10.009

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  18 in total

1.  Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.

Authors:  Yunmin Ding; Lisa Won; Jonathan P Britt; Sean Austin O Lim; Daniel S McGehee; Un Jung Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.

Authors:  Ettel Keifman; Irene Ruiz-DeDiego; Diego Esteban Pafundo; Rodrigo Manuel Paz; Oscar Solís; Mario Gustavo Murer; Rosario Moratalla
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

3.  The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Sara Sanz-Blasco; Melina P Bordone; Ana Damianich; Gimena Gomez; M Alejandra Bernardi; Luciana Isaja; Irene R Taravini; Diane P Hanger; M Elena Avale; Oscar S Gershanik; Juan E Ferrario
Journal:  Mol Neurobiol       Date:  2017-08-24       Impact factor: 5.590

4.  Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

Authors:  Hanna Iderberg; Natallia Maslava; Analisa D Thompson; Michael Bubser; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones; M Angela Cenci
Journal:  Neuropharmacology       Date:  2015-03-04       Impact factor: 5.250

5.  D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

Authors:  Irene Sebastianutto; Elise Goyet; Laura Andreoli; Joan Font-Ingles; David Moreno-Delgado; Nathalie Bouquier; Céline Jahannault-Talignani; Enora Moutin; Luisa Di Menna; Natallia Maslava; Jean-Philippe Pin; Laurent Fagni; Ferdinando Nicoletti; Fabrice Ango; M Angela Cenci; Julie Perroy
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

6.  Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop
Journal:  Exp Neurol       Date:  2020-05-05       Impact factor: 5.330

7.  The phenylephrine blood pressure clamp in pharmacologic magnetic resonance imaging: reduction of systemic confounds and improved detectability of drug-induced BOLD signal changes.

Authors:  Raffael Kalisch; Marina Delfino; M Gustavo Murer; Dorothee P Auer
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

8.  Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Christopher J Barnum; Jessica A George; Margaret A Surrena; Christopher Bishop
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

9.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

10.  Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Authors:  M L Gregório; E C Wietzikoski; M M Ferro; J L M Silveira; M A B F Vital; C Da Cunha
Journal:  Neurotox Res       Date:  2009-03-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.